What is Enovis's prevention & recovery — net sales?

Enovis (ENOV) reported prevention & recovery — net sales of $288.25M in Q2 2026.

What does prevention & recovery — net sales mean?

The total revenue generated from the sale of medical devices and rehabilitation products within the Prevention & Recovery segment, after accounting for returns, allowances, and discounts. This is the primary indicator of the segment's market demand and commercial success in the medical technology space.

Enovis (ENOV) Prevention & Recovery — Net Sales

Screener

Other segment segments

Reconstructive

$294.53M+7.5%

Similar metrics at other companies

AVN

AVNSSurgical pain and recovery — Net Sales

$21.8M-11.0%

AVN

AVNSTotal Pain Management and Recovery — Net Sales

$56.3M+0.2%

CENTPet — Net Sales

$400.5M-18.7%

CNHNet Sales — Net Sales

$2.6B+0.6%

GISPet — Net Sales

$746.6M+5.8%

CLPet Nutrition — Net Sales

$1.2B—

Other financials

Income statement

See full

Revenue$582.8M+3.2%

Gross profit$359.2M+7.3%

Operating income$17.4M+204%

Net income-$1.2M+96.8%

EPS (diluted)-$0.02+96.9%

Balance sheet

See full

Cash & equivalents$12.6M-71.5%

Total debt$1.3B-6.4%

Total equity$1.5B-42.7%

Total assets$3.8B-25.0%

Cash flow

See full

Operating cash flow$75.0M+57.1%

CapEx$43.9M-1.1%

Free cash flow$31.1M—

Valuation

See full

Market cap$1.52B+3.1%

Enterprise value$2.81B-0.4%

P/S0.7×0.0×

Profitability

See full

Gross margin61.1%+3.5pp

Operating margin-45.1%+19.4pp

Net margin-48%+17.7pp

FCF margin-3.1%-1.1pp

Returns & leverage

See full

Return on equity-54.3%+672pp

Debt / equity0.9×+0.3×

Current ratio2×-0.3×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Enovis’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:45 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001420800-26-000035

Line item	Three Months Ended / July 3, 2026	Three Months Ended / July 4, 2025	Six Months Ended / July 3, 2026	Six Months Ended / July 4, 2025
U.S. Bracing & Support	$127,610	$120,850	$242,493	$235,936
U.S. Other P&R (1)	59,637	70,823	115,499	137,445
International P&R	101,001	98,897	202,274	189,773
Total Prevention & Recovery	288,248	290,570	560,266	563,154
Reconstructive:
U.S. Recon	137,829	129,493	287,037	267,370
International Recon	156,705	144,482	324,630	292,855
Total Reconstructive	294,534	273,975	611,667	560,225

Item 1. Financial Statements

FAQ

What is Enovis's prevention & recovery — net sales?: Enovis (ENOV) reported prevention & recovery — net sales of $288.25M in Q2 2026.
What does prevention & recovery — net sales mean?: The total revenue generated from the sale of medical devices and rehabilitation products within the Prevention & Recovery segment, after accounting for returns, allowances, and discounts. This is the primary indicator of the segment's market demand and commercial success in the medical technology space.